Accelerating a process that can cost in excess of £1bn, BenevolentAI’s deep learning platform analyses datasets to identify new drugs. It has launched 24 drug candidates since starting in 2013, and last year signed an £800m licensing deal with a subsidiary of Johnson & Johnson to develop a new treatment for Alzheimer’s. BenevolentAI has raised $87m to date, from investors including Woodford Investment Management and American and Danish pharmaceutical firms. It is valued at a reported $1.7bn, and sales of £2.6m in 2016 are set to rise to £7.5m this year. Founder and director Ken Mulvany, 49, previously led the $553m sale of drug discovery firm Proximagen to US drug maker Upsher-Smith in 2012.

This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.

Company details
Year2017
CompanyBenevolentAI
ActivityDrug discovery & development
LocationCentral London
Latest sales £000s2,585
Forecast sales £000s7,500
Staff80
Founded2013
Websitewww.benevolent.ai

If applicable:

* Sales and forecast sales provided by the companies